Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Hess, Georg [1 ]
Kang, Lisa [2 ]
Moran, Padraig J. [3 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Dublin, PA, Ireland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1165
页数：1
相关论文
共 50 条
  • [21] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M.
    Krekeler, G.
    Neuhof, A.
    Woike, M.
    Hess, G.
    Kalanovic, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M.
    Hess, G.
    Woike, M.
    Krekeler, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 48 - 48
  • [23] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M.
    Hess, G.
    Krekeler, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 72 - 72
  • [24] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M. H.
    Hess, G.
    Woike, M.
    Krekeler, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 362 - 362
  • [25] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M.
    Krekeler, G.
    Neuhof, A.
    Woike, M.
    Hess, G.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 156 - 156
  • [26] EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF TEMSIROLIMUS IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (REL/REFR MCL) IN THE USUAL HEALTH CARE SETTING
    Krekeler, G.
    Herzberg, C.
    Dreyling, M. H.
    Hess, G.
    Kalanovic, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 359 - 360
  • [27] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Dreyling, M.
    Hess, G.
    Krekeler, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in the usual health care setting
    Krekeler, G.
    Herzberg, C.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2012, 35 : 44 - 44
  • [29] TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY
    Hess, G.
    Romaguera, J.
    Herbrecht, R.
    Verhoef, G.
    Crump, M.
    Hanushevsky, O.
    Strahs, A.
    Hewes, B.
    Berkenblit, A.
    Coiffier, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 391 - 392
  • [30] Efficacy and tolerability in clinical practice account best opportunity Temsirolimus for relapsed and/or refractory Mantle cell lymphoma
    Pohlmann, Birgit-Kristin
    ONKOLOGIE, 2010, 33 (12): : 722 - 723
12345